Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100841 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00100841: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00100841 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100841, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab and cetuximab may kill more tumor cells. This phase II trial is studying how well giving combination chemotherapy together with bevacizumab and cetuximab works in treating patients with stage IV colorectal cancer that cannot be removed by surgery.
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- BIOLOGICAL cetuximab
- DRUG leucovorin calcium
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2004-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100841
The ClinicalTrials.gov registry entry for NCT00100841 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT00100841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100841 about?
NCT00100841 is a clinical study titled "Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer". Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and sp...
What is the current status of trial NCT00100841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2004-11. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00100841?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), cetuximab (BIOLOGICAL), leucovorin calcium (DRUG), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00100841?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.